

Special Issue

Therapeutic Potential of Adipose-Derived Stem Cells

Message from the Guest Editors

We are pleased to announce the special issue entitled “Therapeutic Potential of Adipose-Derived Stem Cells (ADSCs)” that aims to collect scientific publications including original and review papers in the field of ADSCs treatment. Due to the easy collection, multi-potentiality, and elevated responsiveness to different environmental stimuli, ADSCs have been an attractive candidate cell in tissue engineering. Mesenchymal stem cell regeneration studies are provided as an alternative to prevent the disadvantages that using grafts to reconstruct injured sites of articular cartilage and peripheral nerve, including limited sources of donor cartilage, scar formation of the sutured site may inhibit regeneration and cause morbidity to donor sites. In this issue, we target basic and preclinical investigations in ADSCs application.

Guest Editors

Dr. Jung-pan Wang

1. Department of Surgery, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112201, Taiwan
2. Department of Orthopaedics & Traumatology, Taipei Veterans General Hospital, Taipei 112201, Taiwan

Dr. Ming-Hsiao Hu

Department of Orthopedic Surgery, National Taiwan University Hospital, Taipei 100229, Taiwan

Deadline for manuscript submissions

closed (28 February 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/107414

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).